EAM
LFCR icon

Eagle Asset Management’s Lifecore Biomedical LFCR Stock Holding History

Eagle Asset Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-110,113
Closed -$1.38M – 646
2014
Q2 		$1.38M Buy
+110,113
New +$1.3M 0.01% 612

Other funds holding LFCR

GC
Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return
KG
Killen Group Berwyn, Pennsylvania $866M AUM 0.25% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return

Eagle Asset Management's LFCR Position: Q3 2014 in Review

Eagle Asset Management sold out of Lifecore Biomedical (LFCR) in Q3 2014, closing a stake of 110,113 shares — an estimated $1.38M sold.

Eagle Asset Management first reported a position in LFCR in Q2 2014 and held it in 1 quarter. The position peaked at $1.38M in Q2 2014. 107 funds tracked by Wall St. Rank hold LFCR as of Q3 2014.

  • Eagle Asset Management reported no remaining Lifecore Biomedical position as of Q3 2014 after selling out during the quarter.
  • Eagle Asset Management sold 110,113 Lifecore Biomedical shares in Q3 2014, an estimated $1.38M.
  • Eagle Asset Management first reported a position in Lifecore Biomedical in Q2 2014 and held it in 1 quarter.
  • Eagle Asset Management's Lifecore Biomedical position peaked at $1.38M in Q2 2014.
  • 107 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q3 2014.

Based on Eagle Asset Management's 13F filing for Q3 2014, filed 14 Oct 2014.